Abstract: A threat detection and response system including at least one sound sensor configured to sense sound within a detection zone and transmit sound data corresponding to the sensed sound. A system gateway including a processor configured to receive the sound data, analyze the sound data to detect a vocal phrase within the sensed sound, determine that the detected vocal phase corresponds to a pre-defined vocal phrase associated with a threat, and communicate an existence of the threat to a recipient device.

Abstract: A threat detection system includes a processor configured to receive a stream of audio data from one or more sensors positioned in or around a space monitored by the threat detection system; extract a portion of the stream of audio data; determine a signal characteristic of the portion of the stream of audio data; after determining that that a portion of the stream is compatible with a first machine learning model, determine a first confidence score for an existence of a threat in the space using the first machine learning model; determine a second confidence score by providing the portion of the stream of audio data, the signal characteristic, and the first confidence score to a second machine learning model; detect the existence of the threat based on based first and/or second confidence scores; and communicate the existence of the threat to a recipient device.

Abstract: A threat detection system includes a processor configured to receive a stream of audio data from one or more sensors positioned in or around a space monitored by the threat detection system; extract a portion of the stream of audio data; determine a signal characteristic of the portion of the stream of audio data; after determining that that a portion of the stream is compatible with a first machine learning model, determine a first confidence score for an existence of a threat in the space using the first machine learning model; determine a second confidence score by providing the portion of the stream of audio data, the signal characteristic, and the first confidence score to a second machine learning model; detect the existence of the threat based on based first and/or second confidence scores; and communicate the existence of the threat to a recipient device.

Abstract: Apparatuses, systems, and methods for treating tissue abnormalities are disclosed. The tissue may be visualized for determining a presence of one or more abnormalities contained therein. Imaging data obtained by visualization may be used to determine the presence of one or more abnormalities. Each of the detected abnormalities may be identified and a treatment plan developed for treating the abnormalities. Treatment may be delivered to the abnormalities according to the treatment plan.

Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Abstract: A cigar holder is adapted to engage with a golf accessory holder provided in the dashboard, or other portion, of a golf cart. The golf accessory holder can take the form or a golf ball holder or a golf tee holder. In general the cigar holder includes an interfacing portion that is configured to engage the golf accessory holder, taking the place of the golf accessory for which the golf accessory holder is configured. There is also a wind shield portion extending upward from the lower interfacing portion, and a cigar holder portion that extends laterally from the wind shield portion.

Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.

Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Abstract: Apparatuses, systems, and methods for treating tissue abnormalities are disclosed. The tissue may be visualized for determining a presence of one or more abnormalities contained therein. Imaging data obtained by visualization may be used to determine the presence of one or more abnormalities. Each of the detected abnormalities may be identified and a treatment plan developed for treating the abnormalities. Treatment may be delivered to the abnormalities according to the treatment plan.

Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.

Abstract: The present invention relates to pyrrolidine sulfonamide analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.

Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.

Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.

Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.

Abstract: An intraocular pressure sensor system has a first pressure sensor located in an anterior chamber of an eye and a remote pressure sensor located remotely from the first pressure sensor. The remote pressure sensor measures or approximates atmospheric pressure. A difference between readings from the first pressure sensor and the remote pressure sensor approximates intraocular pressure.

Abstract: A system for implantation in an eye of a patient includes a flow device sized for implantation into the eye of the patient. The flow device includes a fluid flow passageway and a flow system. The flow system may include a regulator having a magnetic element, and may be displaceable in the fluid flow passageway to affect flow through the fluid flow passageway. The system may also include a control device physically separate from the flow device and configured to be disposed outside the eye, the control device comprising an actuator magnetic field generator configured to act on the magnetic element to adjust the regulator in the flow system to selectively adjust flow through the flow device in response to changes in intraocular pressure.

Abstract: Control of scanning images during ophthalmic surgery may be performed with a scanning controller that interfaces to an optical scanner used with a surgical microscope. A scan control device may receive user input, including hands-free user input, for controlling an overlay image of scanning data that is overlaid on optical image data viewed using the surgical microscope. A selected location for optical scanning may also be displayed and controlled using the scanning controller.